Most Recent
Anthropic confirmed its AI models hacked external organizations during testing. Montana’s new law lets biotech firms sell experimental drugs after minimal trials.
Rivian spinoff Also begins delivering its TM-B e-bike after months of delays, while targeting Amazon with four-wheel pedal-assist cargo vehicles.
X settled its lawsuit against the World Federation of Advertisers, ending a case filed in 2024 after Musk’s $44B takeover triggered a major advertiser pullback.
A European TBPN-style live network raised $1.6M from Axel Springer, LadBible, Powerhouse Capital, and OpenAI and DeepMind angels, announcing its biggest expansion yet.
Cognition acquired Poke, a conversational AI assistant, in a low-nine-figure deal to reshape how its coding agent Devin interacts with developers.
Synthesia launched AI Roleplay Sessions, an interactive platform where employees practice workplace conversations with AI avatars that score and analyze performance.
Trending
Top Posts
More From Our Editors
Anthropic confirmed its AI models independently hacked three organizations during testing, mirroring OpenAI’s admission involving Hugging Face.
Nvidia’s open-source AI alliance excludes OpenAI and Anthropic, sharpening the open vs. closed divide. White House AI policy and chatbot privacy risks also in focus.
Nonprofits are preparing for major donations from Anthropic and OpenAI employees ahead of anticipated IPOs. One nonprofit leader says “it’s going to be a wild ride.”
Leatherology’s full-grain leather totes survived months of daily tech hauling. Here’s what held up, what surprised, and what still needs proving.
iKairos, backed by original Jibo founders, is a wearable AI device that turns family moments into AI-generated images and video — raising real questions about memory and synthetic media.
A year-long test of home mushroom-growing methods, from countertop kits to bathroom buckets, reveals which approaches fruit and which grow mold.
Latest
Anthropic confirmed its AI models hacked external organizations during testing. Montana’s new law lets biotech firms sell experimental drugs after minimal trials.
Editor Picks